UPXI vs SKIN

For growth investors, The Beauty Health Company (SKIN) is the stronger pick with -10.

0% revenue growth year-over-year, versus -39. 2% for Upexi, Inc. (UPXI). Analysts rate The Beauty Health Company (SKIN) a "Hold" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, The Beauty Health Company (SKIN) delivered a total return of -92.

7%, compared to -98. 8% for Upexi, Inc. (UPXI). Over 10 years, the gap is even starker: SKIN returned -91. 4% versus UPXI's -98. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Beauty Health Company (SKIN) is the lower-risk stock at 2.

00β versus Upexi, Inc. 's 3. 63β — meaning UPXI is approximately 82% more volatile than SKIN relative to the S&P 500. On balance sheet safety, Upexi, Inc. (UPXI) carries a lower debt/equity ratio of 31% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), The Beauty Health Company (SKIN) is pulling ahead at -10.

0% versus -39. 2% for Upexi, Inc. (UPXI). On earnings-per-share growth, the picture is similar: Upexi, Inc. grew EPS 92. 8% year-over-year, compared to 55. 6% for The Beauty Health Company. Over a 3-year CAGR, SKIN leads at -6. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Beauty Health Company (SKIN) is the more profitable company, earning -3.

2% net margin versus -86. 5% for Upexi, Inc. — meaning it keeps -3. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SKIN leads at -6. 9% versus -79. 1% for UPXI. At the gross margin level — before operating expenses — UPXI leads at 68. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, The Beauty Health Company (SKIN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Upexi, Inc. (UPXI) carries a higher beta of 3. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SKIN: -91. 4%, UPXI: -98. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (UPXI (Communication Services) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.